AQP4 and myeloid sarcoma: Initially considered a variant of multiple sclerosis (MS), NMOSD was reclassified as a distinct entity following the identification of autoantibodies targeting aquaporin-4 (AQP4), a water channel protein on astrocytes (2, 3).